Poniard Pharmaceuticals (Poniard Pharmaceuticals) Total Stockholders Equity : $3.12 Mil (As of Sep. 2011)

View and export this data going back to 2012. Start your Free Trial

What is Poniard Pharmaceuticals Total Stockholders Equity?

Poniard Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2011 was $3.12 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Poniard Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2011 was $2.08. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Poniard Pharmaceuticals's Debt-to-Equity for the quarter that ended in Sep. 2011 was 0.53.

Poniard Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Poniard Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poniard Pharmaceuticals Total Stockholders Equity Chart

Poniard Pharmaceuticals Annual Data

Trend

Dec01

Dec02

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Total Stockholders Equity

Get a 7-Day Free Trial

46.89

89.11

47.65

23.64

8.45

Poniard Pharmaceuticals Quarterly Data
	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11
Total Stockholders Equity	Get a 7-Day Free Trial															12.13	8.45	9.34	6.28	3.12

Poniard Pharmaceuticals (OTCPK:PARD) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Poniard Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2011 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3.117	-	0.002)	/	1.49861
	=	2.08

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Poniard Pharmaceuticals's Debt-to-Equity for the quarter that ended in Sep. 2011 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	1.64)	/	3.117
	=	0.53

Poniard Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Poniard Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poniard Pharmaceuticals Inc (OTCPK:PARD) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119

Website

http://www.poniard.com

Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.

Executives

Michael S Perry	officer: President & CMO	C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Ron Martell	director, officer: Chief Executive Officer	PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gary A Lyons	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
David R Stevens	director	300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Gerald Phd Mcmahon	director	300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Carl Goldfischer	director	161 WEST 61ST STREET, NEW YORK NY 10022
Fred B Craves	director	750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Simon Nicholas J Iii	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Gregory L Weaver	officer: Chief Financial Officer	185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Kurt Wheeler	10 percent owner	801 GATEWAY BLVD, STE 410, SAN FRANCISCO CA 94080
Mpm Asset Management Investors 2005 Bviii Llc	10 percent owner	C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE 31ST FLOOR, BOSTON MA 02199
Nicholas Galakatos	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Dennis Henner	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Michael Steinmetz	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Luke Evnin	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Headlines

From GuruFocus

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-10-2010

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010

Poniard Pharmaceuticals Inc. (PARD) CFO Gregory L Weaver buys 3,000 Shares

By GuruFocus Research GuruFocus Editor • 08-22-2009

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-06-2009

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 05-12-2009

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 08-09-2010

Poniard Pharmaceuticals Inc. (PARD) CFO Gregory L Weaver buys 2,000 Shares

By gurufocus • 04-06-2009

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-07-2009